Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 19/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 19/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12012339 | 0.82 | CYP11B1 (0.66) | CYP11B1CYP11B2AR | |
| SCHEMBL91991 | 0.81 | CYP11B1 (0.39) | CYP11B1CYP11B2AR | |
| SCHEMBL12011040 | 0.79 | CYP11B1 (0.43) | CYP11B1CYP11B2AR | |
| SCHEMBL4567614 | 0.79 | CYP11B1 (0.57) | CYP11B1CYP11B2AR | |
| SCHEMBL23510030 | 0.77 | CYP11B1 (0.46) | CYP11B1CYP11B2AR | |
| SCHEMBL25573564 | 0.75 | CYP11B1 (0.40) | CYP11B1CYP11B2AR | |
| SCHEMBL23509933 | 0.75 | CYP11B1 (0.40) | CYP11B1CYP11B2AR | |
| SCHEMBL15786642 | 0.75 | CYP11B1 (0.57) | CYP11B1CYP11B2AR | |
| SCHEMBL20005190 | 0.74 | CYP11B1 (0.40) | CYP11B1CYP11B2AR | |
| SCHEMBL25573723 | 0.74 | CYP11B1 (0.56) | CYP11B1CYP11B2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115337-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2021-04-22 | — | — | US | disclosed |
| US-9567522-B2 | Liquid crystal system and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-02-14 | — | — | US | disclosed |
| US-9567522-B2 | Liquid crystal system and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-02-14 | — | — | US | disclosed |
| US-20130193376-A1 | LIQUID CRYSTAL SYSTEM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| US-8409469-B2 | Liquid crystal system and liquid crystal display | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| US-8333906-B2 | Liquid crystal system and liquid crystal display | MERCK PATENT GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-8129002-B2 | Compounds for use in liquid crystal media | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20120012785-A1 | Liquid Crystal System And Liquid Crystal Display | SCHOTT CECILE (TW) | 2012-01-19 | — | — | US | disclosed |
| US-7914859-B2 | Light modulation media, use in particular for electrooptic displays which are operated at a temperature at which the mesogenic modulation media are in an optically isotropic phase, preferably in a blue phase; reduced operating voltage, reduced temperature dependency of operating voltage, reliability | MERCK PATENT GMBH (DE) | 2011-03-29 | — | — | US | disclosed |
| US-20100258763-A1 | LIQUID CRYSTAL SYSTEM AND LIQUID CRYSTAL DISPLAY | SCHOTT CECILE | 2010-10-14 | — | — | US | disclosed |
| US-7794621-B2 | Liquid crystal system and liquid crystal display | MERCK PATENT GMBH (DE) | 2010-09-14 | — | — | US | disclosed |
| US-20090267025-A1 | LIQUID CRYSTAL SYSTEM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| US-7531106-B2 | Mesogenic compounds, medium for electro-optical displays and electro-optical display | MERCK PATENT GMBH (DE) | 2009-05-12 | — | — | US | disclosed |
| US-20080167482-A1 | mesogenic group is linked to the C-atom No. 5 of the 1,3-dioxane-5-yl group; media showing a blue phase and their use in electro-optical light modulation elements | MERCK PATENT GMBH (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | MERCK PATENT GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | CRY1, CRY2, IK | CYP11B1 684/4885CYP11B2 609/4885AR 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.